FDA, Biopharma Prepare for First Wave of Biosimilars
By Mari Serebrov
Thursday, July 21, 2011
With the first wave of biosimilars about to hit, it could be sink-or-swim time for both the FDA and industry as they prepare to dive in.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.